London-based MedTech company CoMind has raised £76.7 million to develop and commercialise its non-invasive brain monitoring technology. This investment is one of the largest European healthtech funding rounds this year.
The funding will be used to complete clinical trials, scale manufacturing, and secure regulatory approval for its first product, CoMind One.
Founded in 2018 by engineer and neuroscientist James Dacombe, CoMind is developing technology that offers doctors continuous, real-time insights into a patient’s brain health without needing invasive procedures. The device measures critical neurological signals, including cerebral blood flow, cerebral autoregulation, and intracranial pressure. This data is vital for making faster, more accurate treatment decisions in intensive care settings.
Current hospital brain monitoring involves a trade-off between iInvasive procedures (drilling into the skull), which are accurate but risky and costly, or non-invasive methods (like ultrasound) that are safer but often unreliable. CoMind’s system is designed to close this gap by combining novel sensor hardware with advanced data analytics to provide critical information reliably at the bedside.
While still in development, CoMind One is expected to be crucial in treating patients with brain injuries, stroke, and trauma, where reliable, continuous monitoring is key to preventing irreversible damage. It could also support research into neurological disorders.
CoMind is currently working towards regulatory submission for CoMind One and building partnerships with hospitals and manufacturers in preparation for commercial deployment.
Image source: PixaBay
